Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 3Leukemia, Lymphocytic, Chronic, B-Cell 3Multiple Myeloma 2Lymphoma, Non-Hodgkin 2Waldenstrom Macroglobulinemia 1Neuroblastoma 1Leukemia, Prolymphocytic, T-Cell 1Hematologic Neoplasms 1Breast Neoplasms 1Amyloidosis 1

Interventions

venetoclax 1niraparib 1ibrutinib 1Sensitivity and Specificity 1Lisaftoclax 1GRN163L peptide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Leukemia, Prolymphocytic, T-Cell × Lisaftoclax × Clear all
NCT04496349 2025-11-04

A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL

Ascentage Pharma Group Inc.

Phase 2 Recruiting
78 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Leukemia, Prolymphocytic, T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡